Abstract |
The role of both autologous (autoSCT) and allogeneic stem cell transplantation (alloSCT) in the management of mantle cell lymphoma (MCL) remains to be clarified. We conducted a consensus project using the RAND-modified Delphi consensus procedure to provide guidance on how SCT should be used in MCL. With regard to autoSCT, there was consensus in support of: autoSCT is the standard first-line consolidation therapy; induction therapy should include high-dose cytarabine and Rituximab; complete or partial remission should be achieved before autoSCT; Rituximab maintenance following autoSCT is not indicated; and omission of autoSCT in 'low-risk' patients is not indicated. No consensus could be reached regarding: autoSCT in the treatment of relapsed disease following non-transplant therapy; the value of positron emission tomography scanning and minimal residual disease (MRD) monitoring; in vivo purging with Rituximab; total body irradiation conditioning for autoSCT; and preemptive Rituximab after autoSCT. For alloSCT, consensus was reached in support of: alloSCT should be considered for patients relapsing after autoSCT; reduced intensity conditioning regimens should be used; allogeneic immunotherapy should be used for MRD eradication after alloSCT; and there is a lack of prognostic criteria to guide the use of alloSCT as first-line consolidation. No consensus was reached regarding the role of alloSCT for relapsed disease following non-transplant therapy.
|
Authors | S Robinson, P Dreger, D Caballero, P Corradini, C Geisler, M Ghielmini, S Le Gouill, E Kimby, S Rule, U Vitolo, M Dreyling, O Hermine, European MCL Network and the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation |
Journal | Leukemia
(Leukemia)
Vol. 29
Issue 2
Pg. 464-73
(Feb 2015)
ISSN: 1476-5551 [Electronic] England |
PMID | 25034148
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal, Murine-Derived
- Cytarabine
- Rituximab
|
Topics |
- Antibodies, Monoclonal, Murine-Derived
(administration & dosage)
- Consensus Development Conferences as Topic
- Cytarabine
(administration & dosage)
- Europe
- Hematopoietic Stem Cell Transplantation
(methods)
- Humans
- Immunotherapy
(methods)
- Lymphoma, Mantle-Cell
(immunology, therapy)
- Neoplasm, Residual
- Positron-Emission Tomography
- Recurrence
- Remission Induction
- Rituximab
- Transplantation Conditioning
(methods)
- Transplantation, Autologous
(methods)
- Transplantation, Homologous
(methods)
- Treatment Outcome
- Whole-Body Irradiation
|